Aileron Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

James Windsor

최고 경영자

US$715.9k

총 보상

CEO 급여 비율	11.9%
CEO 임기	1.1yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

CEO 보상 분석

James Windsor 의 보수는 Aileron Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$29m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$716k	US$85k	-US$16m

보상 대 시장: James 의 총 보상 ($USD 715.92K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 652.28K ).

보상과 수익: James 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

James Windsor (58 yo)

1.1yrs

테뉴어

US$715,921

보상

Dr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Aileron Therapeutics, Inc. from March 11, 2024 and its President. Dr. Windsor served as Chief Operating Officer and President from...

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Windsor	CEO, President & Director	less than a year	US$715.92k	0.033% $ 19.7k
Josef von Rickenbach	Independent Chairman	5.4yrs	US$67.97k	0.10% $ 61.5k
Alan Musso	Independent Director	1.1yrs	US$15.64k	0% $ 0
Carol Prives	Member of Scientific Advisory Board	6.7yrs	데이터 없음	데이터 없음
Brian Druker	Member of Scientific Advisory Board	6.7yrs	데이터 없음	데이터 없음
Alan List	Member of Scientific Advisory Board	6.7yrs	데이터 없음	데이터 없음
Reinhard Ambros	Independent Lead Director	11.4yrs	US$46.25k	0.0013% $ 801.3
William Fairey	Independent Director	1.1yrs	US$9.38k	0% $ 0
Manuel Aivado	Director	6.2yrs	US$630.74k	0.00023% $ 137.5
Ulrich Steidl	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: ALRN 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.

Aileron Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Financial position

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령